Nektar Therapeutics (NKTR) Stock: Buy, Sell, or Hold?
NKTR - Nektar Therapeutics
$37.12
-1.53 (-3.96%)
▼
5d:
+3.75%
30d:
-37.49%
90d:
-47.97%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When NKTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NKTR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NKTR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NKTR is currently trading at $37.12, which is considered oversold relative to its 30-day fair value range of $37.62 to $61.91.
Technical Outlook: Technically, NKTR is in a strong uptrend. Immediate support is located at $35.61, while resistance sits at $42.38. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $133.08 (+244.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NKTR is in a strong uptrend. Immediate support is located at $35.61, while resistance sits at $42.38. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $133.08 (+244.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$37.62 -
$61.91
Company Quality Score
62/100
(BUY)
Options IV Signal
33th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 33th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 244.3% below Wall St target ($133.08)
- NEUTRAL: Bottoming setup forming (55/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$37.62 -
$61.91
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.80
(10.2%)
Support & Resistance Levels
Support Level
$35.61
Resistance Level
$42.38
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.68
Wall Street Target
$133.08
(+244.3%)
Revenue Growth (YoY)
-9.3%
Profit Margin
-287.8%
Share & Embed Analysis
Last updated: October 23, 2026 12:31 PM ET
Data refreshes hourly during market hours. Next update: 1:31 PM
Data refreshes hourly during market hours. Next update: 1:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NKTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
